

INVESTOR PRESENTATION

Quarter Jun-25





AGENDA

▶	<u>Company Overview</u>	01
▶	<u>Vision & Mission</u>	02
▶	<u>Why Invest In Syschem</u>	03
▶	<u>Problem & Solution</u>	04

▶	<u>Future Roadmap</u>	05
▶	<u>Financial Snapshot</u>	06
▶	<u>Geographical Presence</u>	07
▶	<u>ESG Commitment</u>	08

COMPANY OVERVIEW

- Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business.
- The Company is committed to its highly committed team of techno-commercial specialists with considerable expertise in the bulk medicine market. Syschem India Limited has established a firm presence in the business by providing their consumers with high-quality products and services.
- The Company's commitment to research and development, quality assurance, and customer satisfaction has established it as a trusted partner in the pharmaceutical business.



A background pattern of overlapping triangles in various shades of green and grey.

Vision & Mission

Vision

To become a leading and trusted global partner in the chemical and pharmaceutical industry by providing high-quality, innovative, and sustainable solutions. Syschem India Limited is committed to scientific excellence, regulatory compliance, and creating long-term value for customers, employees, and society through ethical and environmentally responsible practices.

Mission

- To be among India's one of the top manufacturers of APIs (antibiotics) and pharmaceutical intermediates.
- To create long-term value for all stakeholders through innovation, operational excellence, and responsible manufacturing.
- To foster a culture of collaboration, growth, and safety across all levels of the organization.
- To continuously invest in R&D and quality systems to meet evolving customer and regulatory needs
- To adopt sustainable practices and reduce environmental impact across the value chain.

WHY INVEST IN SYSCHEM



Over the past few years, Syschem has demonstrated a steady increase in revenue, EBITDA, and profitability, supported by operational efficiency, backward integration, and lean cost structures



Syschem's manufacturing facility in Kalka, Haryana is ISO-certified and aligned with cGMP standards. The company also houses a dedicated R&D division.



Syschem is committed to environmentally responsible manufacturing, employee welfare, and transparent governance – critical parameters for long-term investors.

PROBLEM & SOLUTION

Problem Investor Pitch Deck



STAFF

Syschem India faces challenges in attracting and retaining highly skilled technical personnel due to increasing competition in the APIs and pharmaceutical sectors. The company is also working on upgrading internal training programs to improve process efficiency and ensure safety compliance across all levels.



COMPETITOR

The APIs and pharmaceutical industry is highly competitive, with both domestic and international players offering similar products. Syschem India differentiates itself through its focus on quality, compliance with global standards, and investment in process innovation, but must continually innovate to stay ahead of aggressive pricing and capacity expansions by peers.



BUDGETING

Raw material volatility and foreign exchange exposure impact the company's cost structure. Efficient budgeting and cost optimization across supply chains are critical. Syschem India has initiated strategic sourcing and lean manufacturing practices to mitigate financial pressure and improve margins.



CUSTOMER DEMAND

Growing demand for APIs and pharmaceutical in India and abroad is a strong tailwind. However, meeting evolving regulatory and quality expectations is crucial. Syschem India is expanding capacity and strengthening R&D to align with this rising demand while ensuring consistency and compliance.



FUTURE ROADMAP

Strategic Expansion

Construction of SIL's new manufacturing unit for cloxacillin, dicloxacillin, and flucloxacillin is now underway in Kalka, Haryana.

WHO-GMP Compliance

The upcoming facility will adhere to WHO-GMP guidelines, ensuring the highest standards in quality, safety, and regulatory compliance.

Capacity Enhancement

This expansion will significantly increase production capacity to cater to rising domestic and international demand for β -lactam antibiotics.



Infrastructure Leverage

By utilizing existing infrastructure and technical expertise, SIL ensures cost-effective growth and operational efficiency.


Global Market Strengthening

The move reinforces SIL's position as a trusted API supplier globally and contributes to India's vision of pharmaceutical self-reliance.

FINANCIAL SNAPSHOT


REVENUE

(In Lakhs)




PBT

(In Lakhs)



EBITDA

(In Lakhs)



The company reported a **24%** increase in revenue for the quarter ending June 25 as compared to quarter ending June-24, driven by strong performance across key business segments."




With a PBT of **₹167.4 lakhs** in the recent quarter, the company has demonstrated quarter-on-quarter growth and remains on track to meet its financial goals and indicating positive momentum towards achieving its annual target




The company improved its EBITDA in the quarter ending March 25, as well as in the subsequent quarter ending June 2025, reflecting stronger operational efficiency and cost management."



FINANCIAL SNAPSHOT



The company experienced a modest dip in revenue in the June-25 quarter, attributed to weaker demand early in the new financial year."




We are pleased to report a notable improvement in our earnings per share **0.38** this quarter compared to the previous one.

This growth reflects the strength of our operational execution, ongoing efficiency initiatives, and commitment to delivering long-term value. Your continued trust and support have been instrumental in achieving this milestone. As we move forward, we remain focused on sustainable growth, innovation, and enhancing shareholder returns.

PRODUCTION

(In MT)



95%

The company scaled up its production by **95%** at the end of quarter March 2025, as compared to quarter ended Jun-24, demonstrating enhanced operational capacity and efficient resource utilization.

81%

In the end of quarter Jun-25 also the company scaled up its production by **81%**, as compared to quarter ended Jun-24, demonstrating enhanced operational capacity ,Rapid Growth and efficient resource utilization.

FINANCIAL ABOUTS



QoQ INCREASE

The company reported a 24% quarter-over-quarter increase in revenue for the quarter ending June 25 compared to quarter ending June 24

01



March Quarter Slowdown

The company experienced a modest dip in revenue in the June 25 quarter compared to Mar 25 quarter attributed to weaker demand early in the new financial year

03



Improved Profit Margins

The company improved its EBITDA in the quarter ending March 25, as well as in the subsequent quarter ending June 2025


02



Profits Trending Up


With a PBT of ₹167.4 lakhs in the recent quarter, the company has demonstrated quarter-on-quarter growth and remains on track to meet its financial goals and indicating positive momentum towards achieving its annual target

04




GEOGRAPHICAL PRESENCE

SUPPLY ZONE





Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled service and quality. This expansion involves not just increasing our geographical footprint, but also enhancing our product offerings and service channels to be more accessible and innovative.



DOMESTIC PRESENCE

SUPPLY ZONE



The company has a diverse range of intermediate items in the pharmaceuticals industry that are created chemically. The company has established a foothold in India and the international market; its products have been exported to Latin America, Africa, Thailand, Sri Lanka, Nepal, Indonesia, Germany, Bangladesh, and the MENA area.

Syschem's expansive supply chain network is a testament to its commitment to excellence and reliability. Operating across 12 Indian states and reaching over seven international locations, Syschem has established itself as a formidable player in the global market. This extensive reach ensures that the company can efficiently meet the diverse needs of its customers, maintaining a seamless flow of high-quality products.

ESG Commitment at Syschem India Ltd

- Implementation of sustainable manufacturing practices
- Efficient waste management systems in place
- Focus on reduced energy consumption
- Adoption of green technologies to minimize ecological impact

Environment

- Employee health and safety as a top priority
- Community engagement and upliftment programs
- Inclusive growth and diversity in the workplace
- Promoting a positive and responsible work culture

Social

- Adherence to national and international compliance standards
- Emphasis on ethical conduct and transparency
- Accountability in all business operations
- Robust corporate governance policies to guide decision-making

Governance

SAFE HARBOUR STATEMENT

This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, reliability, or fairness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Presentation or in relation to the bases and assumptions underlying such projections. You must satisfy yourself in relation to the reasonableness, achievability, and accuracy thereof.


Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict.



SAFE HARBOUR STATEMENT

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the wind power industry in India and worldwide, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences, and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance, or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company, and the Company is not responsible for such third-party statements and projections.

No responsibility or liability is accepted for any loss or damage, howsoever arising, that you may suffer as a result of this Presentation. All responsibility and liability are expressly disclaimed by the Management, the Shareholders, and the Company or any of them or any of their respective directors, officers, affiliates, employees, advisers, or agents.



OUR MANAGEMENT TEAM



Mr. Ranjan Jain

Managing Director

With over 25 years of entrepreneurial experience. Mr. Jain has led Syschem's strategic diversification and growth in the pharmaceutical and chemical domain.



Mr. Suninder Veer Singh

Whole-Time Director

He oversees Sales and Marketing, leveraging more than two decades of experience in National and international market.

Mr. Sanjeev Agrawal

Chief Financial Officer

With around 30 years of experience in finance, operations, and business development, he plays a key role in Strategic financial decision-making Optimizing capital structure.



Ms. Shikha Kataria

Company Secretary

She plays a crucial role in ensuring that the company complies with legal and regulatory requirements, Organizes and records minutes of Board Meetings and Annual General Meetings, Prepares and circulates notices, agendas, and resolutions.

CONTACT US

Phone

0172-5070471

Email

info@syschem.in

Website

[Syschem](#)

Location

Head Office : 825, FF, NAC Manimajra ,
Chandigarh-161001

Factory at : Village Bargodam, Tehsil Kalka,
Dist. Panchkula, Haryana-133302



THANK YOU

A Presentation by -

